The m6A regulator KIAA1429 stabilizes RAB27B mRNA and promotes the progression of chronic myeloid leukemia and resistance to targeted therapy

Zhou, 2015, Leukemia stem cells: the root of chronic myeloid leukemia, Protein Cell, 6, 403, 10.1007/s13238-015-0143-7 Shan, 2019, Leukemia stem cells in chronic myeloid leukemia, Adv Exp Med Biol, 1143, 191, 10.1007/978-981-13-7342-8_9 Soverini, 2018, Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy, Mol Cancer, 17, 49, 10.1186/s12943-018-0780-6 Patnaik, 2020, Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management, Am J Hematol, 95, 97, 10.1002/ajh.25684 Braun, 2020, Response and resistance to BCR-ABL1-targeted therapies, Cancer Cell, 37, 530, 10.1016/j.ccell.2020.03.006 Atallah, 2020, Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?, Haematologica, 105, 2738, 10.3324/haematol.2019.242891 Amir, 2021, A review on the therapeutic role of TKIs in case of CML in combination with epigenetic drugs, Front Genet, 12, 742802, 10.3389/fgene.2021.742802 Wu, 2020, Emerging role of m6 A RNA methylation in nutritional physiology and metabolism, Obes Rev, 21, 10.1111/obr.12942 Huang, 2020, The biogenesis and precise control of RNA m6A methylation, Trends Genet, 36, 44, 10.1016/j.tig.2019.10.011 Oerum, 2021, A comprehensive review of m6A/m6Am RNA methyltransferase structures, Nucleic Acids Res, 49, 7239, 10.1093/nar/gkab378 Shen, 2022, Detailed resume of RNA m6A demethylases, Acta Pharm Sin B, 12, 2193, 10.1016/j.apsb.2022.01.003 Zhao, 2020, m6A-binding proteins: the emerging crucial performers in epigenetics, J Hematol Oncol, 13, 35, 10.1186/s13045-020-00872-8 Shi, 2019, Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers, Mol Cell, 74, 640, 10.1016/j.molcel.2019.04.025 Tong, 2018, RNA m6A modification and its function in diseases, Front Med, 12, 481, 10.1007/s11684-018-0654-8 Fazi, 2019, Interplay between N 6-methyladenosine (m6A) and non-coding RNAs in cell development and cancer, Front Cell Dev Biol, 7, 116, 10.3389/fcell.2019.00116 Ianniello, 2019, N6-methyladenosine (m6A): a promising new molecular target in acute myeloid leukemia, Front Oncol, 9, 251, 10.3389/fonc.2019.00251 Kwok, 2017, Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia, J Hematol Oncol, 10, 49, 10.1186/s13045-017-0419-x Weng, 2018, METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification, Cell Stem Cell, 22, 191, 10.1016/j.stem.2017.11.016 Yankova, 2021, Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia, Nature, 593, 597, 10.1038/s41586-021-03536-w Huang, 2019, Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia, Cancer Cell, 35, 677, 10.1016/j.ccell.2019.03.006 Yue, 2018, VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation, Cell Discov, 4, 10, 10.1038/s41421-018-0019-0 Qian, 2019, KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner, Oncogene, 38, 6123, 10.1038/s41388-019-0861-z Miao, 2020, KIAA1429 regulates cell proliferation by targeting c-Jun messenger RNA directly in gastric cancer, J Cell Physiol, 235, 7420, 10.1002/jcp.29645 Cheng, 2019, KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m6A modification of ID2 mRNA, OncoTargets Ther, 12, 3421, 10.2147/OTT.S180954 Xu, 2021, VIRMA contributes to non-small cell lung cancer progression via N6-methyladenosine-dependent DAPK3 post-transcriptional modification, Cancer Lett, 522, 142, 10.1016/j.canlet.2021.08.027 Zhao, 2020, Epigenetic regulation of m6A modifications in human cancer, Mol Ther Nucleic Acids, 19, 405, 10.1016/j.omtn.2019.11.022 Huang, 2020, m6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer, Cancer Cell, 37, 270, 10.1016/j.ccell.2020.02.004 Zhu, 2021, Role of m6A methyltransferase component VIRMA in multiple human cancers (Review), Cancer Cell Int, 21, 172, 10.1186/s12935-021-01868-1 Schwartz, 2014, Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites, Cell Rep, 8, 284, 10.1016/j.celrep.2014.05.048 Li, 2020, Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux, Carcinogenesis, 41, 1583, 10.1093/carcin/bgaa029 Kariya, 2011, Rab27a and Rab27b are involved in stimulation-dependent RANKL release from secretory lysosomes in osteoblastic cells, J Bone Miner Res, 26, 689, 10.1002/jbmr.268 Fukuda, 2013, Rab27 effectors, pleiotropic regulators in secretory pathways, Traffic, 14, 949, 10.1111/tra.12083 Imai, 2004, The small GTPase Rab27B regulates amylase release from rat parotid acinar cells, J Cell Sci, 117, 1945, 10.1242/jcs.01048 Peng, 2018, miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding, Leukemia, 32, 1180, 10.1038/s41375-018-0015-2 Ren, 2016, Overexpression of Rab27B is correlated with distant metastasis and poor prognosis in ovarian cancer, Oncol Lett, 12, 1539, 10.3892/ol.2016.4801 Chiang, 2012, Direct imaging of RAB27B-enriched secretory vesicle biogenesis in lacrimal acinar cells reveals origins on a nascent vesicle budding site, PLoS One, 7, 10.1371/journal.pone.0031789 Wang, 2021, Differential roles of YTHDF1 and YTHDF3 in embryonic stem cell-derived cardiomyocyte differentiation, RNA Biol, 18, 1354, 10.1080/15476286.2020.1850628 Chai, 2021, YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma, J Hematol Oncol, 14, 109, 10.1186/s13045-021-01124-z Zaccara, 2020, A unified model for the function of YTHDF proteins in regulating m6A-modified mRNA, Cell, 181, 1582, 10.1016/j.cell.2020.05.012 Schoenbeck, 2021, Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: current state and future directions, Curr Hematol Malig Rep, 16, 491, 10.1007/s11899-021-00656-y García-Gutiérrez, 2022, A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase, J Hematol Oncol, 15, 90, 10.1186/s13045-022-01309-0 Deng, 2022, m6A modification: recent advances, anticancer targeted drug discovery and beyond, Mol Cancer, 21, 52, 10.1186/s12943-022-01510-2 Jiang, 2021, Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells, J Hematol Oncol, 14, 139, 10.1186/s13045-021-01150-x He, 2022, Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through mediating Bcl2 stability via Ythdf1-mediated m6A modification, Bone, 154, 116182, 10.1016/j.bone.2021.116182 Halbach, 2016, Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells, Cell Commun Signal, 14, 6, 10.1186/s12964-016-0129-y Sacha, 2022, The outcomes of ponatinib therapy in patients with chronic myeloid leukemia resistant or intolerant to previous tyrosine kinase inhibitors, treated in Poland within the donation program, Clin Lymphoma Myeloma Leuk, 22, 405, 10.1016/j.clml.2021.11.012 Gleixner, 2021, Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1T315I-compound mutations, Am J Cancer Res, 11, 4470 Wang, 2014, ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance, PLoS Genet, 10, 10.1371/journal.pgen.1004414 Pinto, 2021, Combined therapy of ATRA and imatinib mesylate decreases BCR-ABL and ABCB1/MDR1 expression through cellular differentiation in a chronic myeloid leukemia model, In Vivo, 35, 2661, 10.21873/invivo.12549 Padella, 2022, Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies, J Hematol Oncol, 15, 10, 10.1186/s13045-022-01228-0 O’Sullivan Coyne, 2022, PARP inhibitor applicability: detailed assays for homologous recombination repair pathway components, Onco Targets Ther, 15, 165, 10.2147/OTT.S278092